NCT00575874View on ClinicalTrials.gov

Placebo and Active Comparator Controlled Dose Response Study of Rivoglitazone in Type 2 Diabetes

PHASE2CompletedINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

August 31, 2007

Primary Completion Date

June 30, 2008

Study Completion Date

January 31, 2009

Conditions
Type 2 Diabetes
Interventions
DRUG

Rivoglitazone HCl

0.5 mg rivoglitazone HCl tablets once daily for 12 weeks

DRUG

rivoglitazone HCl

1.0 mg rivoglitazone HCl tablets once daily for 12 weeks

DRUG

rivoglitazone HCl

1.5 mg rivoglitazone HCl tablets once daily for 12 weeks

DRUG

pioglitazone HCl

30 mg capsules once daily for 12 weeks

DRUG

placebo

matching tablets or capsule once daily for 12 weeks

Trial Locations (1)

Unknown

Hong Kong

Sponsors
All Listed Sponsors
lead

Daiichi Sankyo Co., Ltd.

INDUSTRY

NCT00575874 - Placebo and Active Comparator Controlled Dose Response Study of Rivoglitazone in Type 2 Diabetes | Biotech Hunter | Biotech Hunter